Shopping Cart
Remove All
Your shopping cart is currently empty
Tenalisib (RP6530) (RP6530) is a potent and selective inhibitor of PI3Kδ and PI3Kγ(IC50 values of 25 and 33 nM, respectively.)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | - | In Stock | |
| 2 mg | $45 | - | In Stock | |
| 5 mg | $74 | In Stock | In Stock | |
| 10 mg | $113 | - | In Stock | |
| 25 mg | $198 | - | In Stock | |
| 50 mg | $320 | Inquiry | Inquiry | |
| 100 mg | $482 | Inquiry | Inquiry | |
| 1 mL x 10 mM (in DMSO) | $81 | - | In Stock |
| Description | Tenalisib (RP6530) (RP6530) is a potent and selective inhibitor of PI3Kδ and PI3Kγ(IC50 values of 25 and 33 nM, respectively.) |
| Targets&IC50 | PI3Kδ:25 nM, PI3Kγ:33 nM |
| In vitro | In both HEL-RS and HEL-RR cells, Tenalisib exhibits modest proliferation inhibition (33-46% inhibition @ 10 μM). Addition of 10 μM tenalisib to ruxolitinib is synergistic resulting in a near-complete inhibition of proliferation (>90% for HEL-RS and >70% for HEL-RR). Addition of 5 μM tenalisib, 4 h prior to the addition of ruxolitinib results in a significant reduction in EC50of ruxolitinib (5.8 μM) in HEL-RR cells. |
| In vivo | Single agent(Tenalisib) activity is evident in difficult-to-treat subjects at ≥ 200 mg BID[2]. |
| Synonyms | RP6530 |
| Molecular Weight | 415.42 |
| Formula | C23H18FN5O2 |
| Cas No. | 1639417-53-0 |
| Smiles | CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1 |
| Relative Density. | 1.434 g/cm3 (Predicted) |
| Color | White |
| Appearance | solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (240.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.63 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.